Staff editor

InnoGI Technologies: advancing gut microbiome research with mucus-enhanced models

Maitrayee Chatterjee, Ph.D., Project Manager and Senior Scientist at InnoGI Technologies, discusses their innovative and non-invasive platform to mimic both the upper and lower gastrointestinal tract, offering precise and standardized…

Lallemand Health Solutions launches Cerenity, a clinically studied probiotic formula to support healthy aging

Cerenity™ improves mobility, strength, and muscle function in older adults by modulating the gut-muscle axis.

NIST redefines gut microbiome research with breakthrough reference material

The Human Gut Microbiome Reference Material (RM) promises to standardize and enhance research efforts in a field poised to transform healthcare.

MaaT013 cleared for pediatric trials: EMA approval marks key milestone for microbiome therapy in aGvHD

MaaT013, a Microbiome Ecosystem Therapy™ (MET), is designed to restore the gut microbiome in pediatric patients aged 6 to 18 years with steroid-resistant aGvHD.

Skin microbiome

The skin is not merely a protective barrier; it is a complex, dynamic ecosystem populated by billions of microorganisms that play essential roles in maintaining skin health.

Resetting the immune system: HMOs as a promising treatment for Gut-Brain Axis disorders

Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment. 

Bloom Science’s Live Biotherapeutic BL-001 achieves significant weight loss in Phase 1 trial

Positive results from Phase 1 trial of BL-001, an innovative live biotherapeutic product (LBP) designed to replicate the metabolic effects of the ketogenic diet.

Ferring receives health Canada approval for REBYOTA

The approval is major step forward in the fight against recurrent C. diff infection.

BiomX Secures $12 Million to Drive Phage Therapy Advancements for Cystic Fibrosis Treatment

Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.

Redefining bacterial therapies with CRISPR: Ancillia’s strategy for enhanced efficacy

David Paez-Espino, Co-founder & CTO at Ancilia Biosciences, discusses the use of CRISPR technology to develop a new class of bacterial therapies that address critical gaps in microbiome-based treatments. 

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top